Cargando…

Antipsychotic-Induced Metabolic and Cardiovascular Side Effects in Schizophrenia: A Novel Mechanistic Hypothesis

The use of antipsychotics is hindered by the frequent occurrence of metabolic and cardiovascular side effects, resulting in worsened quality of life and greater mortality as a result of cardiovascular and cerebrovascular disorders in schizophrenia patients than the comparable general population. The...

Descripción completa

Detalles Bibliográficos
Autores principales:	Scigliano, Giulio, Ronchetti, Gabriele
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing AG 2013
Materias:	Current Opinion
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3657088/ https://www.ncbi.nlm.nih.gov/pubmed/23533011 http://dx.doi.org/10.1007/s40263-013-0054-1

Ejemplares similares

Sea otter health: Challenging a pet hypothesis
por: Lafferty, Kevin D.
Publicado: (2015)

Linking Tensegrity to Sports Team Collective Behaviors: Towards the Group-Tensegrity Hypothesis
por: Caldeira, Paulo, et al.
Publicado: (2020)

Fuel for the Work Required: A Theoretical Framework for Carbohydrate Periodization and the Glycogen Threshold Hypothesis
por: Impey, Samuel G., et al.
Publicado: (2018)

24-Hour Physical Behavior Balance for Better Health for All: “The Sweet-Spot Hypothesis”
por: Holtermann, Andreas, et al.
Publicado: (2021)

UK Biobank: opportunities for cardiovascular research
por: Littlejohns, Thomas J, et al.
Publicado: (2019)

Global position paper on cardiovascular regenerative medicine
por: Fernández-Avilés, Francisco, et al.
Publicado: (2017)

Cardiovascular Safety Profile of Dapoxetine during the Premarketing Evaluation
por: Kowey, Peter R., et al.
Publicado: (2012)

Lipoprotein(a) as a cardiovascular risk factor: current status
por: Nordestgaard, Børge G., et al.
Publicado: (2010)

Limitations of the SCORE-guided European guidelines on cardiovascular disease prevention
por: Mortensen, Martin Bødtker, et al.
Publicado: (2017)

Differential epigenetic factors in the prediction of cardiovascular risk in diabetic patients
por: Napoli, Claudio, et al.
Publicado: (2020)

Cardiovascular Risk with Non-steroidal Anti-inflammatory Drugs: Clinical Implications
por: Bello, Alfonso E., et al.
Publicado: (2014)

Cardiovascular Disease and Use of Renin-Angiotensin System Inhibitors in COVID-19
por: Kow, Chia Siang, et al.
Publicado: (2020)

The continuum of personalized cardiovascular medicine: a position paper of the European Society of Cardiology
por: Kirchhof, Paulus, et al.
Publicado: (2014)

Omega-3 Fatty Acid Formulations in Cardiovascular Disease: Dietary Supplements are Not Substitutes for Prescription Products
por: Fialkow, Jonathan
Publicado: (2016)

Insights Into the Results of Sotagliflozin Cardiovascular Outcome Trials: Is Dual Inhibition the Cherry on the Cake of Cardiorenal Protection?
por: Koufakis, Theocharis, et al.
Publicado: (2021)

Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management
por: Chapman, M. John, et al.
Publicado: (2011)

Quality markers in cardiology: measures of outcomes and clinical practice—a perspective of the Spanish Society of Cardiology and of Thoracic and Cardiovascular Surgery
por: López-Sendón, José-Luis, et al.
Publicado: (2016)

The Challenge of Maintaining Metabolic Health During a Global Pandemic
por: King, Andy J., et al.
Publicado: (2020)

Novel Strategies for the Treatment of COVID-19
por: McCarthy, Matthew W.
Publicado: (2022)

Profound reductions in first and total cardiovascular events with icosapent ethyl in the REDUCE-IT trial: why these results usher in a new era in dyslipidaemia therapeutics
por: Boden, William E, et al.
Publicado: (2020)

Should Heartbeats/Training Session Be Considered When Comparing the Cardiovascular Benefits of High-Intensity Interval Aerobic and Moderate-Intensity Continuous Training? A Critical Appraisal
por: Rodrigues, Jhennyfer Aline Lima, et al.
Publicado: (2020)

Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel
por: Borén, Jan, et al.
Publicado: (2020)

Does a Hypertrophying Muscle Fibre Reprogramme its Metabolism Similar to a Cancer Cell?
por: Wackerhage, Henning, et al.
Publicado: (2022)

Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
por: Ference, Brian A., et al.
Publicado: (2017)

ESC Joint Working Groups on Cardiovascular Surgery and the Cellular Biology of the Heart Position Paper: Peri-operative myocardial injury and infarction in patients undergoing coronary artery bypass graft surgery
por: Thielmann, Matthias, et al.
Publicado: (2017)

Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration
por: Ference, Brian A, et al.
Publicado: (2018)

Living myocardial slices: a novel multicellular model for cardiac translational research
por: Perbellini, Filippo, et al.
Publicado: (2020)

Azithromycin in COVID-19 Patients: Pharmacological Mechanism, Clinical Evidence and Prescribing Guidelines
por: Sultana, Janet, et al.
Publicado: (2020)

The proliferating cell hypothesis: a metabolic framework for Plasmodium growth and development()
por: Salcedo-Sora, J. Enrique, et al.
Publicado: (2014)

The modern perspective for long-acting injectables antipsychotics in the patient-centered care of schizophrenia
por: Pietrini, Francesco, et al.
Publicado: (2019)

Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association–European Society of Cardiology
por: Maack, Christoph, et al.
Publicado: (2018)

Clinical recommendations for high altitude exposure of individuals with pre-existing cardiovascular conditions: A joint statement by the European Society of Cardiology, the Council on Hypertension of the European Society of Cardiology, the European Society of Hypertension, the International Society of Mountain Medicine, the Italian Society of Hypertension and the Italian Society of Mountain Medicine
por: Parati, Gianfranco, et al.
Publicado: (2018)

Are the Current Processes and Regulations Fit for Purpose to Deliver Novel Therapies During Pandemics? A Perspective on COVID-19 from the UK
por: Jandu, Rajmeet, et al.
Publicado: (2022)

Simplified treatment algorithm for the management of trauma-induced hemorrhage without viscoelastic testing
por: Casu, Sebastian
Publicado: (2021)

Should Cytochrome P450 Inducers be Used to Accelerate Clearance of Brodifacoum from Poisoned Patients?
por: Rubinstein, Israel, et al.
Publicado: (2019)

Novel Mechanistic Insights into Viral Modulation of Immune Receptor Signaling
por: Sigalov, Alexander B.
Publicado: (2009)

Second-Generation Antipsychotic Drugs for Patients with Schizophrenia: Systematic Literature Review and Meta-analysis of Metabolic and Cardiovascular Side Effects
por: Rognoni, Carla, et al.
Publicado: (2021)

Expert review document part 2: methodology, terminology and clinical applications of optical coherence tomography for the assessment of interventional procedures
por: Prati, Francesco, et al.
Publicado: (2012)

Metabolic Comorbidities and Cardiovascular Disease in Pediatric Psoriasis: A Narrative Review
por: Marani, Andrea, et al.
Publicado: (2022)

The Hypothesis of a “Living Pulse” in Cells
por: Walther-Antonio, Marina, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_1t3lov8sad69c42jrevi9m7lm5